Zurich Cantonal Bank
HRTX icon

Zurich Cantonal Bank’s Heron Therapeutics HRTX Stock Holding History

Zurich Cantonal Bank’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,738
Closed -$22.3K – 2829
2023
Q1 		$22.3K Hold
14,738
– – ﹤0.01% 2734
2022
Q4 		$36.8K Buy
14,738
+5,024
+52% +$16.2K ﹤0.01% 2674
2022
Q3 		$41K Hold
9,714
– – ﹤0.01% 2653
2022
Q2 		$27K Hold
9,714
– – ﹤0.01% 2747
2022
Q1 		$56K Hold
9,714
– – ﹤0.01% 2495
2021
Q4 		$89K Hold
9,714
– – ﹤0.01% 2561
2021
Q3 		$104K Hold
9,714
– – ﹤0.01% 2314
2021
Q2 		$151K Hold
9,714
– – ﹤0.01% 2001
2021
Q1 		$157K Sell
9,714
-2,004
-17% -$35.7K ﹤0.01% 1920
2020
Q4 		$248K Hold
11,718
– – ﹤0.01% 1698
2020
Q3 		$174K Hold
11,718
– – ﹤0.01% 1702
2020
Q2 		$172K Buy
11,718
+1,822
+18% +$29.9K ﹤0.01% 1612
2020
Q1 		$116K Buy
9,896
+4,463
+82% +$83.9K ﹤0.01% 1523
2019
Q4 		$128K Buy
5,433
+1,442
+36% +$31.9K ﹤0.01% 1571
2019
Q3 		$74K Hold
3,991
– – ﹤0.01% 1775
2019
Q2 		$74K Hold
3,991
– – ﹤0.01% 1803
2019
Q1 		$98K Sell
3,991
-756
-16% -$19.8K ﹤0.01% 1594
2018
Q4 		$123K Buy
4,747
+929
+24% +$25.5K ﹤0.01% 1477
2018
Q3 		$121K Buy
3,818
+863
+29% +$32.1K ﹤0.01% 1608
2018
Q2 		$115K Hold
2,955
– – ﹤0.01% 1567
2018
Q1 		$82K Hold
2,955
– – ﹤0.01% 1718
2017
Q4 		$53K Buy
2,955
+1,334
+82% +$21.8K ﹤0.01% 2026
2017
Q3 		$26K Hold
1,621
– – ﹤0.01% 2167
2017
Q2 		$22K Hold
1,621
– – ﹤0.01% 2215
2017
Q1 		$24K Hold
1,621
– – ﹤0.01% 2229
2016
Q4 		$21K Hold
1,621
– – ﹤0.01% 2248
2016
Q3 		$28K Buy
1,621
+300
+23% +$5.57K ﹤0.01% 2059
2016
Q2 		$24K Hold
1,321
– – ﹤0.01% 1956
2016
Q1 		$25K Buy
+1,321
New +$26.1K ﹤0.01% 1872

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Zurich Cantonal Bank's HRTX Position: Q2 2023 in Review

Zurich Cantonal Bank sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 14,738 shares — an estimated $22.3K sold.

Zurich Cantonal Bank first reported a position in HRTX in Q1 2016 and held it in 29 quarters. The position peaked at $248K in Q4 2020. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Zurich Cantonal Bank reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Zurich Cantonal Bank sold 14,738 Heron Therapeutics shares in Q2 2023, an estimated $22.3K.
  • Zurich Cantonal Bank first reported a position in Heron Therapeutics in Q1 2016 and held it in 29 quarters.
  • Zurich Cantonal Bank's Heron Therapeutics position peaked at $248K in Q4 2020.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Zurich Cantonal Bank's 13F filing for Q2 2023, filed 7 Aug 2023.